Your session is about to expire
← Back to Search
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist
Tirzepatide for Pediatric Obesity
Phase 1
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 168 hours postdose
Summary
This trial is testing a medication called tirzepatide to see if it is safe for children who are overweight. The study will check how their bodies handle the drug over a few months. Tirzepatide helps control blood sugar and may reduce hunger, which can aid in weight loss.
Who is the study for?
This trial is for children with obesity, defined as having a BMI ≥ the 95th percentile for their age and sex. They should have tried losing weight through lifestyle changes without success. Girls must be in early puberty (Tanner Stage 1). It's not for those with certain medical conditions like pancreatitis, other causes of obesity, diabetes, or significant recent weight change.
What is being tested?
The study tests Tirzepatide (LY3298176) against a placebo to see how safe it is and how well kids tolerate it. Researchers will also check how the body handles this drug over about 13 weeks, excluding screening time.
What are the potential side effects?
While specific side effects in pediatric participants are being studied, tirzepatide in adults can cause stomach issues like nausea or vomiting, decreased appetite, diarrhea; potential risk of low blood sugar; and possible injection site reactions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ predose up to 168 hours postdose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 168 hours postdose
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary study objectives
PK: Maximum Concentration (Cmax) of Tirzepatide
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC0-tau) of Tirzepatide
Side effects data
From 2022 Phase 3 trial • 210 Patients • NCT0502403240%
Diarrhoea
30%
Nausea
27%
Decreased appetite
23%
Upper respiratory tract infection
19%
Abdominal distension
11%
Vomiting
11%
Gastroenteritis
9%
Flatulence
9%
Abortion induced
7%
Abdominal pain upper
7%
Gingivitis
7%
Amylase increased
7%
Lipase increased
6%
Abdominal pain
6%
Injection site reaction
6%
Menstruation irregular
4%
Hepatic function abnormal
4%
Hyperuricaemia
3%
Uterine polyp
3%
Vaginal infection
3%
Dizziness
1%
Hand fracture
1%
Supraventricular tachycardia
1%
Hiccups
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
10 mg Tirzepatide
15 mg Tirzepatide
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: TirzepatideExperimental Treatment1 Intervention
Tirzepatide administered subcutaneously (SC)
Group II: PlaceboPlacebo Group1 Intervention
Placebo administered SC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tirzepatide
2019
Completed Phase 3
~7520
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Tirzepatide, a dual GIP and GLP-1 receptor agonist, and other GLP-1 receptor agonists like liraglutide and semaglutide, work by mimicking incretin hormones that are released after eating. These hormones stimulate insulin release, inhibit glucagon secretion, slow gastric emptying, and promote satiety, leading to reduced food intake and weight loss.
This is particularly important for obesity patients as these mechanisms help in managing weight and improving metabolic health, thereby reducing the risk of obesity-related complications such as type 2 diabetes and cardiovascular diseases.
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,680 Previous Clinical Trials
3,466,354 Total Patients Enrolled
69 Trials studying Obesity
47,057 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,391 Previous Clinical Trials
428,811 Total Patients Enrolled
52 Trials studying Obesity
25,862 Patients Enrolled for Obesity
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My obesity is caused by a hormonal disorder or a specific genetic condition.I don't have major health issues that could affect drug processing or pose risks with the study drug.I have been diagnosed with type 1 or type 2 diabetes.My BMI is in the top 5% for my age and sex.I am a female and have not started puberty.I have had pancreatitis or other stomach/intestine problems.I have had significant weight loss surgery or related treatments in the last 6 months.
Research Study Groups:
This trial has the following groups:- Group 1: Tirzepatide
- Group 2: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Obesity Patient Testimony for trial: Trial Name: NCT05696847 — Phase 1